Form 4: Cero Therapeutics Holdings Interim Chairman and CEO Converts Preferred Stock and Forfeits Options

Christopher B. Ehrlich, Interim Chairman and CEO of Cero Therapeutics Holdings, converted Series A Preferred Stock into common stock and forfeited employee stock options.

Summary

• On September 25, 2024, Christopher B. Ehrlich, Interim Chairman and CEO of Cero Therapeutics Holdings, converted 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock.
• The conversion was based on a conversion price of $1.00 per share, with each $1,000 of Series A Preferred Stock converting into 19,320 shares of common stock due to adjustments in the terms.
• Ehrlich also forfeited 572,182 employee stock options with an exercise price of $1.77, which were set to expire on March 24, 2034.
• Following these transactions, Ehrlich directly owns 5,791,808 shares of Common Stock and indirectly owns 3,600 shares through a spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures required by the SEC to report changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock may dilute existing shareholders' equity.
• The forfeiture of stock options reduces potential future dilution from option exercises.

Key Dates

Keywords

Cero Therapeutics Holdings, Christopher B. Ehrlich, Series A Preferred Stock, Common Stock, Stock Options, Conversion, Forfeiture, Beneficial Ownership, Form 4